Fighting cancer from a chair

January 25, 2021

Cisplatin has been used to treat cancer since the 1970s. Since then, many other platinum-containing cytostatic drugs have been developed, such as triplatinNC, a highly charged complex that contains three ligand-bridged platinum atoms. Unlike cisplatin, this drug also directly inhibits metastasis. The reason for this seems to be modulation of the geometry of a sugar component of heparan sulfate, an important component of the extracellular matrix, reports a research team in the journal Angewandte Chemie.

Heparan sulfate, a glycosaminoglycan, is a chain of ring-shaped sugar molecules. It is involved in many regulatory processes, as well as in the growth and metastasis of tumors. In order for a tumor to grow and form metastases, the extracellular matrix must be broken up in certain locations to allow cells to migrate. The splitting of heparan sulfate by the enzyme heparanase and the release of certain growth factors that bind to heparan sulfate play an important role in this process.

In order to shed light on the interaction of heparan sulfate with triplatinNC, a team led by Anil K. Gorle, Susan J. Berners-Price, and Nicholas P. Farrell at Griffith University (Brisbane, Australia), and Virginia Commonwealth University and Massey Cancer Center (Richmond, Virginia, USA), used fondaparinux (FPX), a molecule made of five sugar units, as a model for heparan sulfate. A combination of computer calculations and experimental data showed that triplatinNC changes the geometry of a specific sugar component of heparan sulfate (a sulfated iduronic acid). The six-membered ring of the iduronic acid can adopt two different spatial conformations: a chair form or a twist-boat form. In free FPX, the chair and twist-boat forms are in a 35:65 ratio. In the presence of triplatinNC, this shifts to 75:25. In the now preferred chair form, there is a pocket into which the platinum drug fits very well, allowing it to bind strongly. In actual heparan sulfate, the result of the strong bonding by triplatinNC is to effectively block it from being split by heparanase.

A tumor cell line in a synthetic extracellular matrix served as a model for triple-negative breast cancer, which is an aggressive form of cancer that is especially hard to treat. Treatment with heparinase initiated significant cell migration in the model. Prior treatment with triplatinNC significantly reduced cell migration--an effect not seen with cisplatin. The team was also able to confirm the anti-metastatic activity of triplatinNC in tests with mice.

TriplatinNC thus demonstrates dual activity. In addition to a cytotoxic effect caused by its action on DNA, it has an anti-metastatic effect caused by interference with the functionality of heparan sulfate. This opens new possibilities for the design of anti-metastatic platinum complexes.
-end-
About the Author

Dr. Anil Gorle is a Research Fellow in the Institute for Glycomics at Griffith University Australia, where his research interests in metalloglycomics have been developed as part of a long-standing collaboration between Professors Sue Berners-Price and Nicholas Farrell from Virginia Commonwealth University, USA.

https://experts.griffith.edu.au/19052-sue-bernersprice

Wiley

Related Cancer Articles from Brightsurf:

New blood cancer treatment works by selectively interfering with cancer cell signalling
University of Alberta scientists have identified the mechanism of action behind a new type of precision cancer drug for blood cancers that is set for human trials, according to research published in Nature Communications.

UCI researchers uncover cancer cell vulnerabilities; may lead to better cancer therapies
A new University of California, Irvine-led study reveals a protein responsible for genetic changes resulting in a variety of cancers, may also be the key to more effective, targeted cancer therapy.

Breast cancer treatment costs highest among young women with metastic cancer
In a fight for their lives, young women, age 18-44, spend double the amount of older women to survive metastatic breast cancer, according to a large statewide study by the University of North Carolina at Chapel Hill.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.

More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.

New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.

American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.

Read More: Cancer News and Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.